YENOM NOTICIAS
Noticias financieras organizadas para conectar titulares, símbolos, fuente, fecha y sentimiento con tu análisis y operativa.
Si escribes ticker, YENOM prioriza ese instrumento. Si lo dejas vacío puedes explorar el feed general o por tema.
NEW YORK, Sept. 11, 2025 (GLOBE NEWSWIRE) -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholder…
NEW YORK, Sept. 11, 2025 (GLOBE NEWSWIRE) -- Class Action Attorney Juan Monteverde with Monteverde & Associates PC (the “M&A Class Action Firm”), has recovered millions of dollars for shareholders and is recognized as a Top 50 Firm in the…
-- Live moderated video webcast with members of Evofem management team on Wednesday, July 12th at 4:00 p.m. ET -- SAN DIEGO, July 6, 2023 /PRNewswire/ -- Evofem Biosciences, Inc., (OTCQB: EVFM) (the "Company") today announced that Saundra…
-- Increased net product revenue 37% in the first quarter of 2023 vs. prior year quarter -- -- Reduced operating expenses 72% -- -- Decreased loss from operations by 88% -- -- Reaffirms path to positive EBITDA -- SAN DIEGO, June 16, 2023 /…
Increased net product revenue more than 35% in the first quarter of 2023 vs. prior year quarter Reduced operating expenses more than 70% Decreased loss from operations more than 85% Reaffirms path to positive EDITDA SAN DIEGO, June 1, 2023…
-- CUSIP number for Evofem will change to 30048L302 on May 18, 2023 -- -- Ticker symbol will change to "EVFMD" for 20 business days, then revert to "EVFM" -- SAN DIEGO, May 17, 2023 /PRNewswire/ -- Evofem Biosciences, Inc., (OTCQB: EVFM) (…
-- Net product sales more than doubled in 2022 vs. prior year -- -- Reduced total operating expenses by $74.1 million in 2022 vs. 2021, exceeding stated goal -- -- Evofem targeting EBITDA break-even by year-end 2023 -- SAN DIEGO, April 28,…
SAN DIEGO, April 14, 2023 /PRNewswire/ -- Evofem Biosciences, Inc., (OTCQB: EVFM), the maker of Phexxi® (lactic acid, citric acid and potassium bitartrate), today announced the appointment of Ivy Zhang as Chief Financial Officer (CFO) and…
— Improves Phexxi coverage for more than 5.8 million New York lives — — Year-to-date, Evofem has gained Phexxi coverage for more than 22.1 million new lives — SAN DIEGO, April 12, 2023 /PRNewswire/ -- Evofem Biosciences, Inc., (OTCQB: EVFM…
– Company cuts management pay and lowers headcount to decrease operating costs – – Reductions align with corporate goal to reach cash flow break even by year-end 2023 – SAN DIEGO, March 21, 2023 /PRNewswire/ -- Evofem Biosciences, Inc., (O…
SAN DIEGO, March 9, 2023 /PRNewswire/ -- Evofem Biosciences, Inc. (OTCQB: EVFM) is pleased to announce the appointment of Albert Altro as Interim Chief Financial Officer of the Company. He replaces Jay File, who is leaving the Company to e…
-- Phexxi is the first and only hormone-free contraceptive offered by reproductive telehealth leader SimpleHealth to its patients -- SAN DIEGO, Feb. 28, 2023 /PRNewswire/ -- Evofem Biosciences, Inc. (OTCQB: EVFM) announced today that repro…
-- Evofem now has four Orange Book listed patents covering Phexxi into 2033 -- SAN DIEGO, Feb. 27, 2023 /PRNewswire/ -- Evofem Biosciences, Inc. (OTCQB: EVFM) today announced that two additional U.S. patents which cover Phexxi® (lactic aci…
SAN DIEGO, Feb. 23, 2023 /PRNewswire/ -- Evofem Biosciences, Inc. (OTCQB: EVFM), announced today that its Board of Directors has unanimously approved a comprehensive strategic process to explore and evaluate strategic alternatives to maxim…
-- Phexxi is the first and only hormone-free contraceptive in the Favor product portfolio -- SAN DIEGO, Jan. 12, 2023 /PRNewswire/ -- Evofem Biosciences, Inc. (OTCQB: EVFM) announced today that female telehealth leader Favor is now a speci…
SAN DIEGO, Jan. 10, 2023 /PRNewswire/ -- Evofem Biosciences, Inc. (OTCQB: EVFM) today announced that Phexxi® (lactic acid, citric acid, potassium bitartrate) has been added to the Costco Member Prescription Program, giving millions of addi…
-- Medicaid improves Phexxi coverage for more than 3.7 million lives across 11 states -- -- Largest commercial insurer in Michigan and a marquis university plan in Pennsylvania move Phexxi to Preferred formulary position with $0 copay and…
SAN DIEGO, Dec. 29, 2022 /PRNewswire/ -- Evofem Biosciences, Inc. (OTCQB: EVFM) today announced that it has been granted additional time by the OTC Markets Group to file its Quarterly Report on Form 10-Q for the quarter ended September 30,…
SAN DIEGO, Oct. 11, 2022 /PRNewswire/ -- Evofem Biosciences, Inc. (OTCQB: EVFM) announced today that the recently completed Phase 3 EVOGUARD clinical trial evaluating EVO100 for the prevention of chlamydia and gonorrhea infection in women…
-- First Regulatory Approval Outside the U.S. -- SAN DIEGO, Oct. 6, 2022 /PRNewswire/ -- Evofem Biosciences, Inc., (OTCQB: EVFM) today announced that its hormone-free contraceptive vaginal gel has been approved by the Nigerian Regulatory A…
SAN DIEGO, Oct. 3, 2022 /PRNewswire/ -- Evofem Biosciences, Inc., (OTCQB: EVFM) announced today that the trading of its common shares has been upgraded to the OTCQB Venture Market from the OTC Pink Open Market. The Company's ticker symbol…
-- Issuance of U.S. Patent No. 11,439,610 Further Strengthens Evofem's Intellectual Patent Portfolio -- -- Newly Issued Patent Expected to Provide Protection for Phexxi into At Least 2033 -- SAN DIEGO, Sept. 23, 2022 /PRNewswire/ -- Evofem…
-- Dr. Donald WallerHonored by University of IllinoisChicago -- SAN DIEGO, Sept. 19, 2022 /PRNewswire/ -- Evofem Biosciences (OTCPK: EVFM) is pleased to congratulate University of Illinois Chicago (UIC) Professor Emeritus Donald Waller, Ph…
-- One of the Largest Commercial Payers in the U.S. Expands Access to Phexxi® for Women Seeking FDA-Approved, Hormone-Free Contraception -- SAN DIEGO, Sept. 16, 2022 /PRNewswire/ -- Evofem Biosciences, Inc. (OTCPK: EVFM) today announced an…
-- Evofem Gains Forbearance from Debtholders for All Existing Matters-- SAN DIEGO, Sept. 16, 2022 /PRNewswire/ -- Evofem Biosciences, Inc. (OTCPK: EVFM) today announced the successful restructuring of its debt, providing forbearance from i…
-- Conference Call Scheduled for 5:00 p.m. ET -- SAN DIEGO, Aug. 10, 2022 /PRNewswire/ -- Evofem Biosciences, Inc., (EVFM) will hold an investor call as follows: Evofem Biosciences (Nasdaq: EVFM) (PRNewsfoto/Evofem Biosciences, Inc.) Date:…
NEW YORK, NY / ACCESSWIRE / August 9, 2022 / Traders News Source, a leading independent equity research and corporate access firm focused on small and mid-cap publicly traded companies recently issued a new C-Level interview with Evofem Bi…
Evofem Biosciences Inc's (NASDAQ: EVFM) Q2 Phexxi sales increased 42% Y/Y to $6.0 million, reflecting higher ex-factory sales and lower gross-to-net adjustments of 40%. The company's operating expense was reduced by 8% to $30 million and i…
-- 42% growth in Phexxi® (lactic acid, citric acid and potassium bitartrate) net product sales quarter over quarter -- -- Reduced operating expense by 8% and improved loss from operations by 16% -- -- Completed registrational Phase 3 trial…
SAN DIEGO, Aug. 3, 2022 /PRNewswire/ -- Evofem Biosciences, Inc., (Nasdaq: EVFM) today announced the appointment of Jenny Yip, a Managing Partner at life sciences investment fund Adjuvant Capital, to its Board of Directors. The appointment…
In this article, we will discuss the 10 best penny stocks to buy and hold according to Reddit. If you want to skip our discussion on the earnings potential of penny stocks, go directly to 5 Best Penny Stocks to Buy and Hold According to Re…
Phoenix, Arizona--(Newsfile Corp. - August 1, 2022) - The Stock Day Podcast welcomed Evofem Biosciences (NASDAQ: EVFM) ("the Company"), an innovator in women's sexual and reproductive health and the maker of hormone-free contraceptive Phex…
-- Top-line readout of data expected in October 2022 -- -- U.S. regulatory submission planned for the first half of 2023 -- -- Phexxi may become the first-ever woman-controlled prophylactic for the prevention of chlamydia and gonorrhea --…
SAN DIEGO, July 29, 2022 /PRNewswire/ -- Evofem Biosciences, Inc., (Nasdaq: EVFM), a women's healthcare company, today commended the U.S. Department of Health and Human Services, alongside the Departments of Labor and of the Treasury ("the…
-- Conference Call Scheduled for 5:00 p.m. ET -- SAN DIEGO, July 28, 2022 /PRNewswire/ -- Evofem Biosciences, Inc., (Nasdaq: EVFM) will hold a webcast and conference call to discuss financial results and business highlights for the second…
Evocative direct-to-consumer (DTC) campaign has received 12 healthcare and communications industry awards to date and has recently been shortlisted for four more awards. The national campaign features Emmy® Award-winning spokeswoman and ac…